UNSPSC 51283728: Loracarbef monohydrate

This classification denotes a cephalosporin antibiotic with the molecular formula C16H16ClN3O4.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X11EVM5SU, chemically known as 1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((aminophenylacetyl)amino)-3-chloro-8-oxo-, monohydrate, (6r-(6.alpha.,7.beta.(r*)))-, but more generally known as loracarbef monohydrate, which bears US NIH Compound Identifier 60746.

European Medicines Agency schedules loracarbef monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08578MIG. Most nations, for tariff purposes, schedule loracarbef monohydrate under HS 29419000. SMILES: C1CCC(CC1)[C@H](C(=O)N[C@H]2[C@H]3CCC(=C(N3C2=O)C(=O)O)CL)N.O.

UNSPSC 51283728 Loracarbef monohydrate is a Commodity code that shows little relevant recent activity under the code's nominal scope. The four most-recent state and local contract opportunities posted under this code are plainly unrelated to loracarbef monohydrate, a third-generation cephalosporin antibiotic: Seminole County, Florida solicited naloxone and drug deactivation systems; Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer prescription programs; the City of Tampa solicited medical and first aid supplies for its fire department; and Minnesota MMCAP solicited generic multi-source pharmaceuticals and OTC products through authorized wholesalers. None of these opportunities specify loracarbef monohydrate or any beta-lactam antibiotic as a line item.

The mismatch between the code's designation and the actual work posted suggests that state and local procurement offices are either applying the code incorrectly or using it as a catch-all category for pharmaceutical and medical supply purchases that fall outside more specific commodity codes. Vendors monitoring this code for loracarbef monohydrate sales opportunities should treat the recent posting activity as a mislabeling signal rather than as evidence of genuine market demand under the code's intended scope. A more targeted approach—monitoring state health department acquisitions, hospital system RFPs, and institutional formulary updates through direct agency channels rather than UNSPSC code aggregators—would be substantially more productive for pharmaceutical manufacturers seeking state and local business.